Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm





    Chief Complaint


    Organ System


    Patent Pending

    PSA Doubling Time (PSADT) Calculator

    Calculates rate of PSA doubling in prostate cancer (correlates with survival).


    Use in patients with prostate cancer. Do not use for screening or diagnosis.

    When to Use
    Why Use

    • Patients with prostate cancer who have undergone radical prostatectomy or definitive radiation therapy and have biochemical recurrence, defined as confirmed PSA ≥0.2 ng/mL if radical prostatectomy or confirmed PSA rise of ≥2 ng/mL above the nadir PSA level if radiation therapy.

    • PSADT has limited value in prostate cancer screening or diagnosis.

    • For patients with biochemical recurrence of prostate cancer, optimal PSADT calculation should include all PSA values of the individual within two years of initially documented PSA recurrence.

    • Entering more values improves accuracy of estimation.

    • Shorter PSADT reflects faster increase in PSA levels, while longer PSADT reflects a slower increase in PSA levels over time.

    • In patients with biochemical recurrence, PSADT:

      • Predicts risk of metastasis and risk of dying of prostate cancer when combined with other factors such as the Gleason Score and length of time to biochemical recurrence.

      • Helps identify patients more likely to develop clinically significant disease.

      • Helps guide patient selection for salvage local therapy or androgen deprivation therapy.

      • Helps guide utilization and timing of imaging studies.

    • For patients with M0 castration resistant disease, PSADT helps guide patient selection for observation, second generation antiandrogen, androgen metabolism inhibitor, or other secondary hormone treatments.

    • Used in assessment of eligibility for clinical trials.



    Please fill out required fields.

    Next Steps
    Creator Insights
    Dr. Charles R. Pound

    About the Creator

    Charles R. Pound, MD, is the chief of urology in the department of surgery at the University of Mississippi Medical Center in Jackson, MS. He is also a professor of medicine at the University of Mississippi School of Medicine. Dr. Pound’s primary research is focused on urologic malignancy including prostate, bladder, and renal cancers.

    To view Dr. Charles R. Pound's publications, visit PubMed

    Are you Dr. Charles R. Pound? Send us a message to review your photo and bio, and find out how to submit Creator Insights!
    MDCalc loves calculator creators – researchers who, through intelligent and often complex methods, discover tools that describe scientific facts that can then be applied in practice. These are real scientific discoveries about the nature of the human body, which can be invaluable to physicians taking care of patients.
    Content Contributors
    • Nazli Dizman, MD
    About the Creator
    Dr. Charles R. Pound
    Are you Dr. Charles R. Pound?
    Content Contributors
    • Nazli Dizman, MD